FDA 483 - Toyobo Co. Ltd. - February 25, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Toyobo Co. Ltd. in Otsu, Shiga, Japan, a sterile drug manufacturer, was cited for significant deficiencies across its quality system. Observations included failures in discrepancy review, environmental monitoring, aseptic practices, laboratory record completeness, and quality unit oversight, indicating a systemic lack of adherence to GMP principles and data integrity. The firm's practices showed issues with data integrity, personnel training, and validation of critical systems.
ID · 5ddad59f-670f-4370-ad82-1388ad774e79